This is a U.S. news story, published by Yahoo, that relates primarily to Qulipta news.
For more U.S. news, you can click here:
more U.S. newsFor more Qulipta news, you can click here:
more Qulipta newsFor more drug discoveries news, you can click here:
more drug discoveries newsFor more news from Yahoo, you can click here:
more news from YahooOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
oral migraine drug atogepant. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest most other migraine treatments news, medication overuse headaches news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
migraine medicationsGood Morning America
•74% Informative
Atogepant, marketed under the brand Qulipta by the company AbbVie , is one of only two FDA -approved CGRP inhibitors taken as a pill for the prevention of migraine headaches.
Migraines affect nearly one in eight adults in the U.S. in the United States .
VR Score
65
Informative language
58
Neutral language
64
Article tone
formal
Language
English
Language complexity
70
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
medium-lived
External references
2
Source diversity
1
Affiliate links
no affiliate links